Bliss GVS PharmaBOM:506197 -3.87%63 Piotroski F-Score is 7 as of Jul. 05, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates BOM:506197 with a GF Score™ of 63/100 and a GF Value™ of ₹151.49 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Bliss GVS Pharma ranks better than 91.93% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bliss GVS Pharma has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Bliss GVS Pharma's Piotroski F-Score or its related term are showing as below:
BOM:506197'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 7
Current: 7
During the past 13 years, the highest Piotroski F-Score of Bliss GVS Pharma was 7. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Bliss GVS Pharma Piotroski F-Score Related Terms
Bliss GVS Pharma Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:506197 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Bliss GVS Pharma's current Net Income (TTM) was 1,291.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Bliss GVS Pharma's return on assets of this year was 0.099232. Bliss GVS Pharma's return on assets of last year was 0.0695775.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Bliss GVS Pharma's gearing of this year was 0.00952214. Bliss GVS Pharma's gearing of last year was 0.02591845.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Bliss GVS Pharma's current ratio of this year was 4.01770217. Bliss GVS Pharma's current ratio of last year was 4.78514904.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Bliss GVS Pharma's number of shares in issue this year was 107.597. Bliss GVS Pharma's number of shares in issue last year was 106.034.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Bliss GVS Pharma's gross margin of this year was 0.538294. Bliss GVS Pharma's gross margin of last year was 0.48404774.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Bliss GVS Pharma's asset turnover of this year was 0.70748396. Bliss GVS Pharma's asset turnover of last year was 0.66177213.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
0
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bliss GVS Pharma has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Bliss GVS Pharma (BOM:506197) has a Piotroski F-Score of 7 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bliss GVS Pharma and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Bliss GVS Pharma's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Bliss GVS Pharma ranks #79 out of 979 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Bliss GVS Pharma's Piotroski F-Score too high?
Bliss GVS Pharma's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Bliss GVS Pharma's value of 7 is 40% above this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #79 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bliss GVS Pharma has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #79 out of 979 companies for Piotroski F-Score. This places Bliss GVS Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Bliss GVS Pharma's value of 7 is 40% above this benchmark. Historically, Bliss GVS Pharma's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Bliss GVS Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹151.49, compared to a current price of ₹506.15 — trading 234.1% above its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Drug Manufacturers industry median of 5.00. Bliss GVS Pharma's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Piotroski F-Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹506.15 is trading 234.1% above its estimated GF Value™ of ₹151.49.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: ₹151.49 vs. price of ₹506.15 (234.1% above fair value)
Industry Position: 40% above the Drug Manufacturers median (#79 of 979)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
63GF Score
Get the complete analysis for BOM:506197
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
